POLITICO
Get the Prescription Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by CVS Health
On Tap
—
The decision to green-light a controversial Alzheimer’s drug is providing fresh fodder to critics of FDA Acting Commissioner Janet Woodcock.
—
—
The top Democratic tax-writer in the Senate plans to rewrite his previously bipartisan drug pricing bill to include Medicare price negotiation, a move that would endanger GOP support.